M. Bilal Abid: Outcomes of NDMM patients who undergo autoHCT after achieving suboptimal response to induction
M. Bilal Abid, Research Fellow in Cancer Therapeutics at MD Anderson Cancer Center, shared an article by Oren Pasvolsky, et al. on LinkedIn:
“Myeloma Transplant Publication.
Not all patients receive the same standard-of-care induction treatment in the real world for a variety of reasons. And, patients receiving the same treatment respond differently. Hence, it was imperative to examine outcomes of newly diagnosed multiple myeloma (NDMM) patients who undergo autologous haematopoietic cell transplantation (autoHCT) after achieving suboptimal response to induction.
- To address this, we looked at patients at MDACC with NDMM who underwent upfront autoHCT between with a suboptimal pre-transplant response (<VGPR).
- n = 1109
- Median PFS and OS for the entire cohort were 38.6 months and 103.8 months.
- Patients with high-risk cytogenetic abnormalities had a median PFS and OS of 24.8 months and 69.9 months.
- In multivariable analysis, the use of post-transplant maintenance (HR 0.75, p = 0.008) and achieving complete response (CR) at best post-transplant response (HR 0.51, p < 0.001) were associated with superior PFS and OS.
In conclusion, NDMM patients who received upfront autoHCT with a pretransplant response of <VGPR had a median PFS of >3 years and median OS of >8 years. Post-transplant maintenance further improved survival outcomes.”
Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response.
Authors: Oren Pasvolsky, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023